Clinical trials
Inclusion Body Myositis clinical trials
Below are recruiting inclusion body myositis clinical trials, each written for real people, not researchers. We’re tracking 7 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06479863RecruitingEarly Phase 1
Testing a new drug combo for inclusion body myositis
This trial tests a combination of two investigational drugs (pozelimab and cemdisiran) to see if they can help people with sporadic inclusion body myositis, a muscle disease that causes progressive weakness. If the drugs work, they may slow down the disease and help you stay stronger longer.
Austin, TexasAges 45–75 - NCT06536166RecruitingPhase 2
Ruxolitinib for Inclusion Body Myositis
This trial tests the drug ruxolitinib (a JAK inhibitor) for people with inclusion body myositis (IBM), a progressive muscle disease. It aims to see if ruxolitinib can help slow muscle weakness and improve function.
Angers, FranceAges 45 years+ - NCT07374107Recruiting
Patient insights for shaping myositis research
This study asks people with autoimmune muscle diseases (myositis) and their caregivers to share their experiences and insights. By joining, you help shape better research and care for myositis.
New Orleans, LouisianaAges 7 years+ - NCT00017914Recruiting
Understanding muscle inflammation: adult and juvenile myositis study
This research study helps doctors better understand myositis—a group of rare diseases that cause muscle inflammation and weakness. Researchers collect blood samples, medical history, and sometimes muscle biopsies to learn more about what causes these conditions and how to treat them better.
Atlanta, GeorgiaAges 2–100 - NCT07478172Recruiting
Electrical muscle stimulation exercise for neuromuscular disease
This study tests whether whole-body electrical muscle stimulation (using small electrodes on the skin) can help adults with certain neuromuscular diseases exercise and improve muscle strength. It may be an option if you can stand for about 15 minutes at a time and have some muscle strength left.
Columbia, MissouriAges 18 years+ - NCT07072676Enrolling by invitation
Can a walker help prevent falls in neuromuscular disease?
This study tests if using assistive walking devices, after a short training period, can lower the risk of falls in people with neuromuscular diseases. It aims to help you stay steady and safe on your feet.
Bad FeilnbachAges 65–65 - NCT06605612Enrolling by invitation
Falls risk test for people with muscle and nerve conditions
This study is creating a test to predict falls in people with neuromuscular disorders. You will fill out a questionnaire about your fall risk.
München, BavariaAges 18–65
Hear when a new Inclusion Body Myositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for inclusion body myositis?
- Yes. Clin2 currently lists 7 recruiting inclusion body myositis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a inclusion body myositis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a inclusion body myositis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.